Blog - Advanced Medicine In China

3 months ago

2024EHA | Professor Huang He: Targeting CD7 Universal CAR-T Therapy Shows Significant Efficacy and Good Safety in Treating R/R CD7+ T-ALL/LBL Patients

**2024EHA | Professor Huang He: Targeting CD7 Universal CAR-T Therapy Shows Significant Efficacy and Good Safety in Treating R/R CD7+ T-ALL/LBL Patients** The 29th Annual Meeting of the European H...

3 months ago

May 1, 2018 Kymriah DLBCL Approval in the U.S. FDA

May 1, 2018 Kymriah DLBCL Approval in the U.S. FDA On May 1, 2018, the FDA approved Kymriah for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL). Kymriah is ...

3 months ago

Kymriah Cell Therapy of CAR-T

Kymriah Cell Therapy of CAR-T Kymriah, also known by its generic name tisagenlecleucel, is a groundbreaking cell therapy used to treat certain types of blood cancers. Developed by Novartis, Kymriah...

3 months ago

Kymriah CD19-Targeted CAR-T Therapy

Kymriah CD19-Targeted CAR-T Therapy Kymriah (tisagenlecleucel) is a groundbreaking CAR-T (Chimeric Antigen Receptor T-cell) therapy developed for the treatment of certain types of blood cancers. He...

3 months ago

China’s Breakthrough in CAR-T Therapy for CNS Lymphoma

### China’s Breakthrough in CAR-T Therapy for CNS Lymphoma Lymphoma In a pioneering effort to improve outcomes for patients with refractory/relapsed central nervous system lymphoma (CNSL), a multi-...

3 months ago

China’s Urological Technology Leads the Way! Over 100 International Doctors from More than 40 Countries Come to Learn

China’s Urological Technology Leads the Way! Over 100 International Doctors from More than 40 Countries Come to Learn China’s Urological ## Innovative Breakthroughs in Urology ChinaR...

3 months ago

Kymriah CAR-T Cell Therapy: A Comprehensive Overview

Kymriah CAR-T Cell Therapy: A Comprehensive Overview Introduction Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of immunotherapy. It is a chimeric antigen receptor...

3 months ago

Kymriah Approved Indications

Kymriah Approved Indications Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of cancer immunotherapy. As a chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah ...

3 months ago

Kymriah Approval FDA

Kymriah Approval FDA On April 22, 2020, Novartis announced that the U.S. Food and Drug Administration (FDA) granted Kymriah® (tisagenlecleucel) Regenerative Medicine Advanced Therapy (RMAT) designa...

3 months ago

Kymriah Approval DLBCL

Kymriah Approval DLBCL As of May 1, 2018, the FDA has approved Novartis’ CD19-targeted CAR-T therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory...

3 months ago

Kymriah Approval Date

Kymriah Approval Date Introduction to Kymriah Kymriah (tisagenlecleucel) is a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy developed by Novartis. It represents a novel approach t...

3 months ago

2024 EHA | New Generation BCL-2 Inhibitor Sonrotoclax Expected to Be a New Treatment Option for RRMM

**2024 EHA | New Generation BCL-2 Inhibitor Sonrotoclax Expected to Be a New Treatment Option for RRMM** RRMM The 29th Annual Meeting of the European Hematology Association (EHA) was held from Ju...

Menu

Our Blog